GlobalData on MSN12d
Lilly’s EBGLYSS shows improvement in Phase IIIb study for atopic dermatitisThe ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.
Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, ...
Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...
Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, either. I'm especially keeping my eyes on the company's oral obesity drug ...
Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback